Metsera was acquired by Pfizer in 2025, which means Pfizer's principal visible triple-agonist exposure is via these two preclinical assets
If it isnt, they may be able to offer an alternative weight loss treatment
We use experimentally determined forms for these allosteric interactions but sometimes the details of the kinetics are not known, forcing us to make reasonable educated guesses
Repeat: patients typically run 2 to 3 full cycles per year

Anyone receiving retatrutide within a clinical trial should seek prompt medical advice from their trial team if they experience any of the following: Persistent or severe vomiting that prevents adequate fluid or food intake Signs of dehydration , including dizziness, reduced urination, or extreme thirst Severe or persistent abdominal pain , which may rarely indicate pancreatitis or a gallbladder problem Right upper quadrant pain, fever, or jaundice , which may suggest acute gallbladder disease (cholelithiasis or cholecystitis) a recognised risk with GLP-1-based therapies and with rapid weight loss [11] [12] Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas), such as shakiness, sweating, or confusion Injection site reactions that are worsening, infected, or not resolving Retatrutide has not been studied in pregnancy or breastfeeding, and use during pregnancy or whilst breastfeeding is not recommended until safety data are available

Duncan: Some people should be on it long term